Fig. 5From: Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerAntitumor Activity of TAK-960 as Measured by Tumor Growth Inhibition Index (TGII) in CRC Patient-Derived Tumor Xenograft Models (PDX). TGII = treated over control, thus lower numbers indicate greater tumor response. 6/18 (33%) models were considered sensitive with TGII < 20. Genetic mutations are indicated by colored boxes.Back to article page